(5,6-Diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic acid
CAS: 701223-63-4
Rif. 3D-BDB22363
1g | Fuori produzione | ||
10mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione | ||
250mg | Fuori produzione | ||
500mg | Fuori produzione |
Informazioni sul prodotto
The use of 5,6-diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic acid (DDP) for cancer therapy has been shown to be effective in wild-type mice. DDP inhibits the growth of human cancer cells by inhibiting the synthesis of DNA and RNA. It also has a cytotoxic effect on tumour cells and increases the production of nitric oxide, which is involved in cell death. The treatment with DDP induces apoptosis and autophagy in human breast cancer cells and synergistic effects with other drugs such as doxorubicin.